BioPharmX adds Mike Hubbard to the Board as Independent Director

– USA, Ca – BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company’s audit committee. Hubbard’s appointment brings the board’s total number of members to four.

“We are delighted with Mike’s decision to join BioPharmX’s board of directors,” said Jim Pekarsky, chief executive officer and co-founder of BioPharmX.  “His breadth and depth of experience serving companies of all sizes from venture-backed to Fortune 500 entities and across several sectors – including life sciences – will be invaluable as we continue to position BioPharmX for growth.”

Throughout his career Hubbard had served as a senior audit partner − at Deloitte & Touche LLP prior to retiring and also at PricewaterhouseCoopers LLP.  In these roles he served private and publicly held clients across the life sciences, waste management, construction, and technology sectors, advising domestic and international issuer companies on complex transactions, including 19 IPOs and numerous follow-on equity and debt offerings.  Hubbard holds a B.A. degree in Business Administration with a concentration in Accounting and an MBA degree from Washington State University.  He is a licensed CPA in the states of Washington and California and is a certified (by Deloitte & Touche LLP) practitioner of international financial reporting standards.

About BioPharmX Corporation

BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>